These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14713557)

  • 1. Society of toxicologic pathology position on assessment of hyperplastic lesions in rodent carcinogenicity studies.
    Boorman G; Dixon D; Elwell M; Kerlin R; Morton D; Peters T; Regan K; Sullivan J;
    Toxicol Pathol; 2004; 32(1):124-5. PubMed ID: 14713557
    [No Abstract]   [Full Text] [Related]  

  • 2. Society of toxicologic pathology position paper: diet as a variable in rodent toxicology and carcinogenicity studies.
    Nold JB; Keenan KP; Nyska A; Cartwright ME
    Toxicol Pathol; 2001; 29(5):585-6. PubMed ID: 11695576
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of hyperplastic lesions in rodent carcinogenicity studies.
    Boorman G; Dixon D; Elwell M; Kerlin R; Morton D; Peters T; Regan K; Sullivan J;
    Toxicol Pathol; 2003; 31(6):709-10. PubMed ID: 14585740
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP).
    Bregman CL; Adler RR; Morton DG; Regan KS; Yano BL;
    Toxicol Pathol; 2003; 31(2):252-3. PubMed ID: 12696587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically induced preneoplastic lesions in rodents as indicators of carcinogenic activity.
    Williams GM
    IARC Sci Publ; 1999; (146):185-202. PubMed ID: 10353388
    [No Abstract]   [Full Text] [Related]  

  • 6. The Society of Toxicologic Pathology's position on statistical methods for rodent carcinogenicity studies.
    Morton D
    Toxicol Pathol; 2001; 29(6):670-2. PubMed ID: 11794383
    [No Abstract]   [Full Text] [Related]  

  • 7. The "rodent carcinogen" dilemma: formidable challenge for the technologies of the new millennium.
    Johnson FM
    Ann N Y Acad Sci; 2000; 919():288-99. PubMed ID: 11083119
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
    Kirkland D; Aardema M; Müller L; Makoto H
    Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology and tissue sampling protocols for rodent carcinogenicity studies: time for revision.
    Leblanc B
    Toxicol Pathol; 2000; 28(4):628-33. PubMed ID: 10930051
    [No Abstract]   [Full Text] [Related]  

  • 11. Transgenic assays and the identification of carcinogens.
    Tennant R; Haseman J; Stoll RE
    Environ Mol Mutagen; 2001; 37(1):86-92. PubMed ID: 11170246
    [No Abstract]   [Full Text] [Related]  

  • 12. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of the spectrum of proliferative lesions observed in the kidney and urinary bladder of Fischer 344 rats and B6C3F1 mice.
    Wolf JC
    Toxicol Pathol; 2002; 30(6):657-62. PubMed ID: 12512865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplement 1, Toxicologic Pathology, March/April 2004 should be must reading for all pathologists.
    Wagner BM
    Toxicol Pathol; 2004; 32(5):613. PubMed ID: 15603545
    [No Abstract]   [Full Text] [Related]  

  • 15. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights of International meeting on Alternative Methods of Carcinogenicity Testing, Leesburg, VA, November 1-3, 2000, Sponsored by the Health and Environmental Sciences Institute.
    Jollow DJ
    J Agromedicine; 2004; 9(2):427-9. PubMed ID: 19785235
    [No Abstract]   [Full Text] [Related]  

  • 17. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
    Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
    Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of reduced protocols for carcinogenicity testing of chemicals: report of a joint EPA/NIEHS workshop.
    Lai DY; Baetcke KP; Vu VT; Cotruvo JA; Eustis SL
    Regul Toxicol Pharmacol; 1994 Apr; 19(2):183-201. PubMed ID: 8041916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Forum.
    Peden WM
    Toxicol Pathol; 2016 Dec; 44(8):1069-1071. PubMed ID: 27753636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.